Effects of half dose etanercept (25 mg once a week) on clinical remission and radiographic progression in patients with rheumatoid arthritis in clinical remission achieved with standard dose

Clinical and Experimental Rheumatology

Volumn 33, Issue 1, 2015, Pages 63-68

  Raffeiner, Bernd ^a   Botsios, Costantino ^a   Ometto, Francesca ^a   Bernardi, Livio ^a   Stramare, Roberto ^a   Todesco, Silvano ^a   Sfriso, Paolo ^a   Punzi, Leonardo ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Disease activity score; Etanercept; Low dose; Radiographic progression; Remission; Rheumatoid arthritis

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN G; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; COST CONTROL; DAS28; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; INFECTION; INFECTION RISK; JOINT RADIOGRAPHY; LONG TERM CARE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REMISSION; RHEUMATOID ARTHRITIS; UNSPECIFIED SIDE EFFECT; AGED; ARTHRITIS, RHEUMATOID; ARTHROGRAPHY; CHEMICALLY INDUCED; COMMUNICABLE DISEASE; COST BENEFIT ANALYSIS; DRUG ADMINISTRATION; DRUG EFFECTS; ECONOMICS; IMMUNOLOGY; ITALY; JOINT; PATHOLOGY; PREDICTIVE VALUE; RADIOGRAPHY; TIME; TREATMENT OUTCOME;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ARTHROGRAPHY; COMMUNICABLE DISEASES; COST SAVINGS; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; DRUG COSTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN G; ITALY; JOINTS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RECEPTORS, TUMOR NECROSIS FACTOR; REMISSION INDUCTION; TIME FACTORS; TREATMENT OUTCOME;

EID: 84928700885     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. SCOTT DL, WOLFE F, HUIZINGA TW: Rheumatoid arthritis. Lancet 2010; 376: 1094-108.
2. MORELAND LW, SCHIFF MH, BAUMGARTNER SW et al.: Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999; 130: 478-86.
3. WEINBLATT ME, KREMER JM, BANKHURST AD et al.: A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340: 253-9.
4. LETHABY A, LOPEZ-OLIVO MA, MAXWELL L, BURLS A, TUGWELL P, WELLS GA: Etanercept for the treatment of rheumatoid arthritis. Cochrane Database Syst Rev 2013; 5: CD004525.
5. FURST DE: The risk of infections with biologic therapies for rheumatoid arthritis. Semin Arthritis Rheum 2010; 39: 327-46.
6. ARNETT FC, EDWORTHY SM, BLOCH DA et al.: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
7. OMETTO F, BOTSIOS C, RAFFEINER B et al.: Methods: used to assess remission and low disease activity in rheumatoid arthritis. Autoimmun Rev 2010; 9: 161-4.
8. BRUYNESTEYN K, van der HEIJDE D, BOERS M et al.: Determination of the minimal clinically important difference in rheumatoid arthritis joint damage of the Sharp/van der Heijde and Larsen/Scott scoring methods by clinical experts and comparison with the smallest detectable difference. Arthritis Rheum 2002; 46: 913-20.
9. DEAN AG, SULLIVAN KM, SOE MM: OpenEpi: Open Source Epidemiologic Statistics for Public Health, Version 2.3.1. [Last updated 2011/23/06, Accessed 2014/02/25]. Available from: www.OpenEpi.com.
10. KAWAI S, SEKINO H, YAMASHITA N, TSUCHIWATA S, LIU H, KORTH-BRADLEY JM: The comparability of etanercept pharmacokinetics in healthy Japanese and American subjects. J Clin Pharmacol 2006; 46: 418-23.
11. TRACEY D, KLARESKOG L, SASSO EH, SALFELD JG, TAK PP: Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008; 117: 244-79.
12. CATRINA AI, AF KLINT E, ERNESTAM S et al.: Anti-tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis. Arthritis Rheum 2006; 54: 76-81.
13. KUBOTA A, HASEGAWA K, SUGURO T, KOSHIHARA Y: Tumor necrosis factor-alpha promotes the expression of osteoprotegerin in rheumatoid synovial fibroblasts. J Rheumatol 2004; 31: 426-35.
14. ARIZA-ARIZA R, NAVARRO-SARABIA F, HERNANDEZ-CRUZ B, RODRIGUEZ-ARBOLEYA L, NAVARRO-COMPAN V, TOYOS J: Dose escalation of the anti-TNF-alpha agents in patients with rheumatoid arthritis. A systematic review. Rheumatology (Oxford) 2007; 46: 529-32.
15. SIMARD JF, ARKEMA EV, SUNDSTROM A et al.: Ten years with biologics: to whom do data on effectiveness and safety apply?. Rheumatology (Oxford) 2011; 50: 204-13.
16. LEOMBRUNO JP, EINARSON TR, KEYSTONE EC: The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis 2009; 68: 1136-45.
17. SMOLEN JS, NASH P, DUREZ P et al.: Main-tenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet 2013; 381: 918-29.
18. KOBELT G, LEKANDER I, LANG A, RAFFEINER B, BOTSIOS C, GEBOREK P: Cost-effectiveness of etanercept treatment in early active rheumatoid arthritis followed by dose adjustment. Int J Technol Assess Health Care 2011; 27: 193-200.
19. TANAKA Y, HIRATA S, SALEEM B, EMERY P: Discontinuation of biologics in patients with rheumatoid arthritis. Clin Exp Rheumatol 2013; 31 (Suppl. 78): 22-7.
20. ALLAART CF, LEMS WF, HUIZINGA TW: The Best way of withdrawing biologic agents. Clin Exp Rheumatol 2013; 31 (Suppl. 78): S14-18.